In a small group of Asian NSCLC patients (n = 14) with acquired MET amplification after EGFR-TKI therapy, Crizotinib both in monotherapy and in combination with an EGFR-TKI provided promising outcomes with median PFS (mPFS) of 6.0 and 12.6 months, respectively [46]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.